Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Loading...
More

Supplementary Data — Quercetin for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, May 2024, Version 21V21
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 94% 0.06 [0.01-0.45] ICU 0/76 8/76 Di Pierro (RCT) 68% 0.32 [0.14-0.70] hosp. 7/76 22/76 Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​1 Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​1 Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​1 Di Pierro (RCT) 67% 0.33 [0.01-7.99] death 0/50 1/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] ICU 0/50 1/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] hosp. 0/50 1/50 Di Pierro (RCT) 37% 0.63 [0.46-0.88] no recov. 24/50 38/50 Di Pierro (RCT) 58% 0.42 [0.27-0.65] viral+ 16/50 38/50 Di Pierro (RCT) -50% 1.50 [0.26-8.60] viral+ 3/50 2/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] viral+ 0/50 1/50 Din Ujjan (RCT) 29% 0.71 [0.50-1.03] no recov. 15/25 21/25 CT​1 Din Ujjan (RCT) 71% 0.29 [0.14-0.59] no recov. 6/25 21/25 CT​1 Din Ujjan (RCT) 77% 0.23 [0.07-0.71] no recov. 3/25 13/25 CT​1 Din Ujjan (RCT) 86% 0.14 [0.01-2.63] no recov. 0/25 3/25 CT​1 Din Ujjan (RCT) 91% 0.09 [0.01-1.56] viral+ 0/25 5/25 CT​1 Din Ujjan (RCT) 74% 0.26 [0.12-0.59] viral+ 5/25 19/25 CT​1 Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1 Onal (RCT) 94% 0.06 [0.00-31.8] ICU 0/49 14/380 CT​1 Onal (RCT) 78% 0.22 [0.03-1.58] no disch. 1/49 35/380 CT​1 Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Zupanets (RCT) 18% 0.82 [0.68-0.98] recov. time 99 (n) 101 (n) Shohan (RCT) 86% 0.14 [0.01-2.65] death 0/30 3/30 Shohan (RCT) 40% 0.60 [0.16-2.29] ICU 3/30 5/30 Shohan (RCT) 32% 0.68 [0.47-0.98] recov. time 30 (n) 30 (n) Gérain (RCT) 67% 0.33 [0.01-7.70] death 0/25 1/24 CT​1 Gérain (RCT) 91% 0.09 [0.01-0.71] death/ICU 0/25 5/24 CT​1 Gérain (RCT) 89% 0.11 [0.01-1.92] ventilation 0/25 4/24 CT​1 Gérain (RCT) 89% 0.11 [0.01-1.92] ICU 0/25 4/24 CT​1 Gérain (RCT) 73% 0.27 [0.06-1.19] no disch. 2/25 7/24 CT​1 Gérain (RCT) 59% 0.41 [0.19-0.89] no disch. 6/25 14/24 CT​1 Gérain (RCT) 38% 0.62 [0.44-0.88] hosp. time 25 (n) 24 (n) CT​1 Gérain (RCT) 50% 0.50 [0.26-0.97] no recov. 22 (n) 24 (n) CT​1 Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1 Margolin 94% 0.06 [0.00-0.93] cases 0/53 9/60 CT​1 Margolin 81% 0.19 [0.04-0.80] cases 2/53 12/60 CT​1 Rondanelli (DB RCT) 93% 0.07 [0.01-0.91] symp. case 1/60 4/60 Quercetin COVID-19 outcomes c19early.org May 2024 1 CT: study uses combined treatment Favors quercetin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit